Sandbox-ID-Skin and Soft Tissues: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 39: | Line 39: | ||
* Impetigo, bullous and nonbullous<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530 }} </ref> | * Impetigo, bullous and nonbullous<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530 }} </ref> | ||
:* Causative pathogens | :* Causative pathogens | ||
::* Staphylococcus aureus | ::* Staphylococcus aureus | ||
::* β-hemolytic | ::* Streptococcus, β-hemolytic | ||
:* Impetigo, adult | :* Impetigo, adult | ||
| Line 47: | Line 47: | ||
::::* Preferred regimen: [[Mupirocin]] topically bid for 5 days {{or}} [[Retapamulin]] topically bid for 5 days | ::::* Preferred regimen: [[Mupirocin]] topically bid for 5 days {{or}} [[Retapamulin]] topically bid for 5 days | ||
:::* '''Numerous lesions or outbreaks of | :::* '''Numerous lesions or outbreaks of poststreptococcal glomerulonephritis''' | ||
::::* Preferred regimen: [[Dicloxacillin]] 250 mg PO qid for 7 days {{or}} [[Amoxicillin-Clavulanate]] 875/125 mg PO bid for 7 days {{or}} [[Cephalexin]] 250 mg PO qid for 7 days | ::::* Preferred regimen: [[Dicloxacillin]] 250 mg PO qid for 7 days {{or}} [[Amoxicillin-Clavulanate]] 875/125 mg PO bid for 7 days {{or}} [[Cephalexin]] 250 mg PO qid for 7 days | ||
::::* Alternative regimen (for penicillin-allergic patients): [[Doxycycline]] 100 mg PO bid for 7 days {{or}} [[Clindamycin]] 300–400 mg PO qid for 7 days {{or}} [[Sulfamethoxazole-Trimethoprim]] 1–2 double-strength tablets PO bid for 7 days | ::::* Alternative regimen (for penicillin-allergic patients): [[Doxycycline]] 100 mg PO bid for 7 days {{or}} [[Clindamycin]] 300–400 mg PO qid for 7 days {{or}} [[Sulfamethoxazole-Trimethoprim]] 1–2 double-strength tablets PO bid for 7 days | ||
Latest revision as of 16:36, 9 June 2015
Skin and Soft Tissues
Acne vulgaris ⇧ Return to Top ⇧
Acne rosacea ⇧ Return to Top ⇧
Anthrax, cutaneous ⇧ Return to Top ⇧
Bacillary angiomatosis ⇧ Return to Top ⇧
Bite wounds ⇧ Return to Top ⇧
Bubonic plague ⇧ Return to Top ⇧
Carbuncle ⇧ Return to Top ⇧
Cat scratch disease ⇧ Return to Top ⇧
Cellulitis ⇧ Return to Top ⇧
Ecthyma ⇧ Return to Top ⇧
Erysipelas ⇧ Return to Top ⇧
Erysipeloid ⇧ Return to Top ⇧
Erythrasma ⇧ Return to Top ⇧
Fournier gangrene ⇧ Return to Top ⇧
Furuncle ⇧ Return to Top ⇧
Gas gangrene ⇧ Return to Top ⇧
Glanders ⇧ Return to Top ⇧
Impetigo ⇧ Return to Top ⇧
- Impetigo, bullous and nonbullous[1]
- Causative pathogens
- Staphylococcus aureus
- Streptococcus, β-hemolytic
- Impetigo, adult
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of poststreptococcal glomerulonephritis
- Preferred regimen: Dicloxacillin 250 mg PO qid for 7 days OR Amoxicillin-Clavulanate 875/125 mg PO bid for 7 days OR Cephalexin 250 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300–400 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 1–2 double-strength tablets PO bid for 7 days
- Pathogen-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 250–500 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 250 mg PO qid for 7 days OR Clindamycin 300–400 mg PO qid for 7 days
- Staphylococcus aureus, methicillin-resistant (MRSA)
- Preferred regimen: Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300–450 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 1–2 double-strength tablets PO bid for 7 days
- Impetigo, pediatric
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of poststreptococcal glomerulonephritis
- Preferred regimen: Amoxicillin-Clavulanate 25 mg/kg/day of amoxicillin component PO bid for 7 days OR Cephalexin 25–50 mg/kg/day PO tid–qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Clindamycin 25–30 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 8–12 mg/kg/day PO bid for 7 days
- Pathogen-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 60,000–100,000 U/kg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 40 mg/kg/day PO tid–qid for 7 days OR Clindamycin 20 mg/kg/day PO tid for 7 days
- Staphylococcus aureus, methicillin-resistant (MRSA)
- Preferred regimen: Clindamycin 25–30 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 8–12 mg/kg/day PO bid for 7 days
Lyme disease, cutaneous ⇧ Return to Top ⇧
Mastitis ⇧ Return to Top ⇧
Necrotizing fasciitis ⇧ Return to Top ⇧
Pilonidal cyst ⇧ Return to Top ⇧
Pyomyositis ⇧ Return to Top ⇧
Seborrheic dermatitis ⇧ Return to Top ⇧
Skin and soft tissue infection in neutropenic fever ⇧ Return to Top ⇧
Skin and soft tissue infection in cellular immunodeficiency ⇧ Return to Top ⇧
Surgical site infection ⇧ Return to Top ⇧
Tularemia ⇧ Return to Top ⇧
Vascular insufficieny ulcer ⇧ Return to Top ⇧
Vibrio infection ⇧ Return to Top ⇧
Wound infection ⇧ Return to Top ⇧
Yaws ⇧ Return to Top ⇧
- ↑ Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.